Open AccessEffect of murine double‐minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys
Author(s) -
Kawata Yoshiko,
Nagasaka Kazunori,
Oda Katsutoshi,
Makii Chinami,
Takeuchi Makoto,
Oki Shinya,
Honjo Harunori,
Kojima Machiko,
Miyagawa Yuko,
Taguchi Ayumi,
Tanikawa Michihiro,
Sone Kenbun,
Hiraike Haruko,
Matsumoto Yoko,
WadaHiraike Osamu,
Ayabe Takuya,
Osuga Yutaka,
Fujii Tomoyuki
Publication year - 2020
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.14583
Subject(s) - ovarian cancer , cancer research , ascites , ovarian carcinoma , renal cell carcinoma , ehrlich ascites carcinoma , clear cell carcinoma , temsirolimus , cell , medicine , clear cell renal cell carcinoma , clear cell , carcinoma , biology , cancer , oncology , pi3k/akt/mtor pathway , signal transduction , tumor cells , biochemistry , genetics , discovery and development of mtor inhibitors
Advanced clear cell carcinomas originating from both ovaries and kidneys with cancerous peritonitis have poor prognoses. Murine double‐minute 2 (MDM2) is a potential therapeutic target for clear cell ovarian carcinomas with WT TP53 . Herein, we characterized the antiangiogenic and antitumor effects of the MDM2 inhibitors DS‐3032b and DS‐5272 in 6 clear cell ovarian carcinoma cell lines and 2 clear cell renal carcinoma cell lines, as well as in clear cell ovarian carcinomas s.c. xenograft and ID8 (murine ovarian cancer cells with WT TP53 ) cancer peritonitis mouse models. In clear cell ovarian carcinoma s.c. xenograft mouse models, DS‐3032b significantly reduced WT TP53 clear cell ovarian carcinoma‐ and clear cell renal carcinoma‐derived tumor volumes. In ID8 mouse models, DS‐5272 significantly inhibited ascites production, reduced body weight, and significantly improved overall survival. Additionally, DS‐5272 reduced the tumor burden of peritoneal dissemination and decreased CD31 + cells in a dose‐dependent manner. Furthermore, DS‐5272 significantly decreased vascular endothelial growth factor concentrations in both sera and ascites. Combined therapy with MDM2 inhibitors and everolimus showed synergistic, and dose‐reduction potential, for clear cell carcinoma treatment. Our findings suggest that MDM2 inhibitors represent promising molecular targeted therapy for clear cell carcinomas, thereby warranting further studies to evaluate the efficacy and safety of dual MDM2/mTOR inhibitors in clear cell carcinoma patients.